CHP adds capacity

Cedarburg Hauser Pharmaceuticals has expanded its Wisconsin API plant by 50% to meet commercial demand. The company has also added reactor and chiller capacity for GMP cryogenic reactions, made improvements to the air handling systems, installed a reverse osmosis water system, improved isolation capabilities, and upgraded their Emerson DeltaV Digital Automation System.
Cedarburg Hauser Pharmaceuticals

Lonza will develop and manufacture Intellect Neurosciences antibody drug conjugate Conjumab-A

Intellect Neurosciences

Market rumours suggest that BASF or Sabic may be looking to acquire Lonza for around £2.2bn

Lonza

17 Socma member facilities have qualified for the ChemStewards Excellence Tier

Socma

Carbogen Amcis has partnered with ADC Biotechnology to provide customers with seamless development and manufacturing services for antibody drug conjugates

Carbogen Amcis

Gallus BioPharmaceuticals and Roslin Cells will provide manufacturing services cell therapy-based biopharmaceutical products customers

PR Web

India plans to establish a competent authority to meet EU API import requirements from July 2013

In-pharma Technologist

Dishman has licenced statin synthesis technology from Redx Pharma to enhance its CRAMS portfolio

Business Standard

The European Commission has revised its GMP guidelines to align them with ICH Q10

In-pharma Technologist

Navidea blames manufacturer

Navidea Biopharmaceuticals attributed the Complete Response Letter from the US Food and Drug Administration regarding its NDA for Lymphoseek to issues with third-party contract manufacturers. In November 2009, Navidea appointed Reliable Biopharmaceutical Corporation for the manufacture and supply of the API for Lymphoseek. Final product manufacturing including final drug formulation, lyophilization and packaging processes for Lymphoseek is performed by OSO BioPharmaceuticals Manufacturing LLC.
Reuters

Boehringer Ingelheim implements disposable biomanufacturing

Boehringer Ingelheim has implemented single-use biomanufacturing at its mammalian facilities worldwide. The system can incorporate different commercially available single-use systems in 100L and 500L GMP facilities for clinical material supplies or for non-GMP process development.
Biopharmaceutical Business Review

Cambridge Major to add capacity

Cambridge Major Laboratories is to expand its large scale API manufacturing facility in Germantown, WI, as a result of growth in demand. The company will add reactor capacity and isolation equipment. Brian Scanlan, President & CEO of Cambridge Major, said that the company's "invest in the West" policy continues to bear fruit. He added that the company is "very well positioned to support both increasing demand for our commercial products as well as our healthy pipeline of API's in later phases of clinical development."
Milwaukee Business Journal

Codexis to cut 133 jobs after deal with Shell terminated

In-pharma Technologist

GE Healthcare has launched a range of modular biomanufacturing facilities

In-pharma Technologist

Piramal Healthcare is rumoured to be in talks to acquire Ind-Swift Laboratories' CRAMS business and facilities

Business Standard

Aesica Partners with University of Bradford

Aesica has partnered with the Centre for Pharmaceutical Engineering Science at the University of Bradford. Aesica will benefit from the University's research facilities and the University will gain access to Aesica's GMP manufacturing facilities.
Manufacturing Chemist

Mike Ironside has been appointed as General Manager, TTC, at Hovione

Hovione